Herpes zoster: Burden of disease in France

Vaccine

Volumn 28, Issue 50, 2010, Pages 7933-7938

  Gonzalez Chiappe, S ^a,b   Sarazin, M ^a,b   Turbelin, C ^a,b   Lasserre, A ^a,b   Pelat, C ^a,b   Bonmarin, I ^c   Chosidow, O ^b,d   Blanchon, T ^a,b   Hanslik, T ^a,b,e,f  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT DE VEILLE SANITAIRE   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Herpes zoster; Hospitalization; Mortality

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; FRANCE; GROUPS BY AGE; HERPES ZOSTER; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; FEMALE; FRANCE; HERPES ZOSTER; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SENTINEL SURVEILLANCE; YOUNG ADULT;

EID: 78650241974     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.074     Document Type: Article

References (32)

1. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4(1):26-33.
2. National Institute of Statistics and Economic Studies (INSEE). [last accessed in July 2010]. http://www.insee.fr/fr/themes/tableau.asp%3Freg_id=0%26ref_id=NATTEF02107.
3. National Institute for Public Health Surveillance (InVS). [last accessed in July 2010]. http://www.invs.sante.fr/surveillance/cancers/estimations_cancers/default.htm.
4. Simon D. Epidemiological features of type 2 diabetes. Rev Prat 2010, 60(4):469-473.
5. Gnann J.W., Whitley R.J. Clinical practice. Herpes zoster. N Engl J Med 2002, 347(5):340-346.
6. Reynolds M.A., Chaves S.S., Harpaz R., Lopez A.S., Seward J.F. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008, 197(Suppl. 2):S224-S227.
7. Flahault A., Blanchon T., Dorléans Y., Toubiana L., Vibert J.F., Valleron A.J. Virtual surveillance of communicable diseases: a 20-year experience in France. Stat Methods Med Res 2006, 15(5):413-421.
8. Chauvin P., Valleron A.J. Attitude of French general practitioners to the public health surveillance of communicable diseases. Int J Epidemiol 1995, 24(2):435-440.
9. Programme de Médicalisation des Systèmes d'Information. [last accessed in January 2009]. http://www.le-pmsi.fr/.
10. Service Commun d'Information sur les Causes Médicales de Décès (CépiDC-INSERM). [last accessed in January 2008]. http://www.cepidc.vesinet.inserm.fr/.
11. Lin Y.-H., Huang L.M., Chang I.S., Tsai F.Y., Lu C.Y., Shao P.L., et al. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine 2010, 28(5):1217-1220.
12. Czernichow S., Dupuy A., Flahault A., Chosidow O. Herpes zoster: incidence study among sentinel general practitioners. Ann Dermatol Venereol 2001, 128(4):497-501.
13. Chidiac C., Bruxelle J., Daures J.P., Hoang-Xuan T., Morel P., Leplege A., et al. Characteristics of patients with herpes on presentation to practitioners in France. Clin Infect Dis 2001, 33(1):62-69.
14. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
15. Jackson L.A., Reynolds M.A., Harpaz R. Hospitalizations to treat herpes zoster in older adults: causes and validated rates. Clin Infect Dis 2008, 47(6):754-759.
16. Di Legami V., Gianino M., Atti M., Massari M., Migliardi A., Tomba G.S., et al. Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine 2007, 25(43):7598-7604.
17. Opstelten W., Mauritz J.W., de Wit N.J., van Wijck A.J., Stalman W.A., van Essen G.A. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002, 19(5):471-475.
18. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clements K.M., et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the behavioral risk factor surveillance system (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005, 5:68.
19. Jumaan A., Yu O., Jackson L., Bohlke K., Galil K., Seward J. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005, 191(12):2002-2007.
20. Mullooly J.P., Riedlinger K., Chun C., Weinmann S., Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005, 133(2):245-253.
21. Patel M.S., Gebremariam A., Davis M.M. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect Control Hosp Epidemiol 2008, 29(12):1157-1163.
22. Lin F., Hadler J.L. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000, 181(6):1897-1905.
23. Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001, 127(2):305-314.
24. de Melker H., Berbers G., Hahné S., Rümke H., van den Hof S., de Wit A., et al. The epidemiology of varicella and herpes zoster in the Netherlands: implications for varicella virus vaccination. Vaccine 2006, 24(18):3946-3952.
25. Chinen J., Shearer W.T. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010, 125(2):195-203.
26. Gil A., San-Martin M., Carrasco P., Gonzalez A. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004, 22(29-30):3947-3951.
27. Opstelten W., Van Essen G.A., Schellevis F., Verheij T., Moons K.G. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006, 16(9):692-695.
28. Gauthier A., Breuer J., Carrington D., Martin M., Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137(1):38-47.
29. Hanslik T., Blanchon T., Alvarez F. Vaccination des adultes contre la varicelle. Rev Med Interne 2007, 28(3):166-172.
30. Opstelten W., van Loon A.M., Schuller M., van Wijck A.J., van Essen G.A., Moons K.G., et al. Clinical diagnosis of herpes zoster in family practice. Ann Fam Med 2007, 5(4):305-309.
31. Boglium G., Beghi E. Validity of hospital discharge diagnosis for public health surveillance of the Guillain-Barré syndrome. Neurol Sci 2002, 23:113-117.
32. Brisson M., Edmunds W.J. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003, 70(1):9-14.